Acumen Pharmaceuticals (ABOS) News Today $1.40 +0.02 (+1.09%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 02/21/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period ABOS stock touches 52-week low at $1.31 amid market challengesFebruary 11, 2025 | msn.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest UpdateAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 31st total of 1,430,000 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.February 2, 2025 | marketbeat.comABOS stock touches 52-week low at $1.52 amid market challengesJanuary 31, 2025 | msn.comPromising US Penny Stocks To Consider In January 2025January 25, 2025 | finance.yahoo.comAcumen Pharmaceuticals chief medical officer sells $5,118 in sharesJanuary 24, 2025 | msn.comAcumen Pharmaceuticals CFO sells shares totaling $56,619January 24, 2025 | msn.comDaniel Joseph Oconnell Sells 12,619 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockJanuary 24, 2025 | insidertrades.comMatt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 28,902 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the sale, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.January 23, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,619 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total value of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares of the company's stock, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.January 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for ABOS FY2025 EarningsAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Acumen Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the companyJanuary 23, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Growth in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 15th total of 1,430,000 shares. Currently, 3.5% of the shares of the stock are sold short. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.January 18, 2025 | marketbeat.comAcumen stock touches 52-week low at $1.54 amid market challengesJanuary 17, 2025 | msn.comAcumen announces Phase 1 INTERCEPT-AD study publicationJanuary 10, 2025 | finance.yahoo.comRussell Barton Sells 7,636 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockJanuary 8, 2025 | insidertrades.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) COO Sells 7,636 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) COO Russell Barton sold 7,636 shares of the business's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $1.86, for a total value of $14,202.96. Following the transaction, the chief operating officer now owns 89,231 shares in the company, valued at approximately $165,969.66. This trade represents a 7.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Insider Eric Siemers Sells 10,859 SharesAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider Eric Siemers sold 10,859 shares of the company's stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $1.85, for a total value of $20,089.15. Following the sale, the insider now owns 106,717 shares of the company's stock, valued at $197,426.45. This represents a 9.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.January 7, 2025 | marketbeat.comMatt Zuga Sells 13,235 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 13,235 shares of the company's stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total transaction of $24,352.40. Following the completion of the transaction, the chief financial officer now owns 198,210 shares of the company's stock, valued at approximately $364,706.40. The trade was a 6.26 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Sells $87,911.52 in StockAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 47,778 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the completion of the transaction, the chief executive officer now owns 454,707 shares in the company, valued at approximately $836,660.88. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.January 7, 2025 | marketbeat.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 5.4% in NovemberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 1,390,000 shares, a decrease of 5.4% from the November 15th total of 1,470,000 shares. Based on an average daily volume of 202,200 shares, the short-interest ratio is currently 6.9 days. Currently, 3.1% of the shares of the stock are short sold.December 17, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNovember 26, 2024 | globenewswire.comHC Wainwright Has Pessimistic View of ABOS FY2024 EarningsAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Research analysts at HC Wainwright dropped their FY2024 earnings estimates for shares of Acumen Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will pNovember 18, 2024 | marketbeat.comAcumen Pharmaceuticals Advances Alzheimer’s TherapeuticNovember 14, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)November 14, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research note on Wednesday.November 13, 2024 | marketbeat.comQ3 2024 Acumen Pharmaceuticals Inc Earnings CallNovember 13, 2024 | uk.finance.yahoo.comAcumen Pharmaceuticals Inc (ABOS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 13, 2024 | finance.yahoo.comAcumen Pharmaceuticals' Shares Drop on Wider 3Q LossNovember 13, 2024 | marketwatch.comAcumen Pharma Reports Q3 2024, Highlights Alzheimer’s FocusNovember 13, 2024 | markets.businessinsider.comAcumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comAcumen Pharmaceuticals Earnings PreviewNovember 12, 2024 | benzinga.comAcumen Pharmaceuticals to Participate in the Stifel Healthcare ConferenceNovember 11, 2024 | globenewswire.comAcumen appoints Schacterle as Chief Regulatory Officer, Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceNovember 6, 2024 | globenewswire.comAcumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of QualityNovember 6, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (ABOS) Scheduled to Post Earnings on TuesdayAcumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comAcumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trialNovember 1, 2024 | markets.businessinsider.comAcumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease ConferenceOctober 31, 2024 | globenewswire.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in OctoberAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 1,270,000 shares, a decline of 18.6% from the September 30th total of 1,560,000 shares. Based on an average trading volume of 203,200 shares, the short-interest ratio is currently 6.3 days. Approximately 2.8% of the shares of the stock are short sold.October 28, 2024 | marketbeat.comAcumen to deliver late-breaking presentation on ACU193 at CTAD conferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 24, 2024 | markets.businessinsider.comAcumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 23, 2024 | globenewswire.comAcumen Pharmaceuticals (NASDAQ:ABOS) Stock, Insider Trading ActivityOctober 21, 2024 | benzinga.comAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Decline in Short InterestAcumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,560,000 shares, a drop of 7.7% from the September 15th total of 1,690,000 shares. Approximately 3.5% of the company's shares are short sold. Based on an average trading volume of 254,100 shares, the short-interest ratio is presently 6.1 days.October 16, 2024 | marketbeat.comMillennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Millennium Management LLC lessened its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 25.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,954,085 shares of the company's stock after selling 675,456October 13, 2024 | marketbeat.comRenaissance Technologies LLC Invests $818,000 in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)Renaissance Technologies LLC purchased a new stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 338,100 shares of the company's stock, valued at approximately $818,000. RenOctober 8, 2024 | marketbeat.comBuy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Sabirnetug Alzheimer’s Treatment DataOctober 4, 2024 | markets.businessinsider.comStrong Buy Rating for Acumen Pharmaceuticals Amid Promising Trial Results for Lead Candidate ACU193October 4, 2024 | markets.businessinsider.comAcumen Pharmaceuticals (NASDAQ:ABOS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Acumen Pharmaceuticals in a research report on Thursday.October 3, 2024 | marketbeat.comAcumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual ConferenceSeptember 30, 2024 | globenewswire.comAcumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s DiseaseSeptember 26, 2024 | finance.yahoo.com Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ABOS Media Mentions By Week ABOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABOS News Sentiment▼0.000.60▲Average Medical News Sentiment ABOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABOS Articles This Week▼02▲ABOS Articles Average Week Get Acumen Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MBX News Today ACB News Today TERN News Today FHTX News Today TSHA News Today CYRX News Today ANNX News Today CRVS News Today TRVI News Today CMPS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABOS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABOS Stock Alerts